Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus and Minimal Steroids with Daclizumab or MMF in Liver Transplantation
NCT00295594Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2005
- Primary completion
- Jun 2007
- Modality
- RNA-Targeting Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in Liver transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoints: Biopsy Proven Acute Rejection at 3 months and Time to First Biopsy Proven Acute Rejection at 3 months. Started Mar 2005; status: completed.
02
Drugs
tacrolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00295594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295594.